Article

Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea

In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.

In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
Hadar Avihai Lev-Tov, MD
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo